Krystal Biotech CEO Krish S. Krishnan and R&D President Suma Krishnan sold nearly $18 million in company stock. These transactions occurred on September 4, 2026. The company disclosed the sales in regulatory filings on September 5.
CEO Krish S. Krishnan sold 25,900 shares. This sale generated approximately $8.98 million. Suma Krishnan sold 27,000 shares. Her sale also totaled approximately $8.98 million.
Both executives used pre-arranged Rule 10b5-1 trading plans adopted on September 4, 2025. The transactions occurred as the stock trades near its 52-week high. The company has seen a significant stock rally over the past year.